I-Mab to Attend Significant Investor Conferences
I-Mab (NASDAQ: IMAB), a pioneering global biotech company, actively involved in creating advanced immuno-oncology treatments for cancer, has made an important announcement regarding its upcoming engagements in the investment community. The management team of I-Mab is poised to participate in two major investor conferences scheduled for September; these events are vital for sharing insights into their groundbreaking work in cancer treatment.
Conference Details
The specific details for the conferences are as follows:
Cantor Global Healthcare Conference
This event will provide one-on-one meetings aimed at facilitating focused discussions between company representatives and potential investors. The conference is set to take place from September 3 to 5.
H.C. Wainwright 27th Annual Global Investment Conference
On September 10, I-Mab will be presenting at the H.C. Wainwright conference, featuring a company presentation followed by one-on-one meetings. The presentation starts at 9:30 AM ET. Investors and stakeholders will have the opportunity to explore the company’s strategic initiatives and advancements in their product pipeline.
I-Mab's Innovative Oncological Focus
I-Mab’s commitment to developing precision immuno-oncology therapies reflects their essential role in advancing cancer treatment. Their leading candidate, givastomig, is a bispecific antibody aimed at targeting Claudin 18.2-positive gastric cancers. This innovative treatment is designed to activate T cells specifically within the tumor microenvironment, a promising approach that enhances the immune response against cancer while reducing prevalent toxicities associated with traditional therapies.
Recent Developments and Future Outlook
As I-Mab progresses through its clinical trials, the early data emerging from Phase 1 studies is encouraging. Givastomig’s robust tumor-binding and anti-tumor activity highlight its potential not just for gastric cancers but also for treating other solid tumors. I-Mab is dedicated to optimizing the therapeutic efficacy of givastomig, anticipating significant advancements in their clinical program.
About I-Mab
I-Mab continues to establish itself as a leader in the biopharmaceutical sector, focusing on innovative treatment avenues for cancer. With a diverse pipeline of therapeutic candidates, they aim to improve patient outcomes in oncology. Their commitment to research and development is matched by their goal of addressing unmet medical needs, driving further innovation in the fight against cancer.
I-Mab Investor & Media Contacts
For investor inquiries or media-related questions, individuals can reach out to PJ Kelleher at LifeSci Advisors via phone at +1-617-430-7579 or through email at pkelleher@lifesciadvisors.com. Additionally, contact can be made through their investor relations email at IR@imabbio.com.
Frequently Asked Questions
What is I-Mab focused on?
I-Mab is focused on developing precision immuno-oncology agents for cancer treatment, aiming to create effective therapies tailored to specific cancer types.
When are the conferences I-Mab is attending?
I-Mab will attend the Cantor Global Healthcare Conference from September 3 to 5 and the H.C. Wainwright Conference on September 10.
What is givastomig?
Givastomig is I-Mab's leading candidate that targets Claudin 18.2-positive gastric cancers, utilizing a bispecific antibody mechanism to activate T cells in the tumor environment.
How can investors get updates about I-Mab?
Investors can access updates through I-Mab's News & Events page on their official website and follow them on LinkedIn for real-time information.
Who can be contacted for investor relations?
For investor inquiries, PJ Kelleher from LifeSci Advisors can be contacted via phone or email mentioned above.
